Posted by Michael Wonder on 15 Sep 2016
TGA approves new indication for Alprolix
15 September 2016 - The TGA has approved a new use for Biogen's Alprolix.
The TGA approved Alprolix (eftrenonacog alfa) on 7 September 2016 for use in children 12 years of age or under with haemophilia B.
